| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5408 | 2010 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3583 | 2014 |
| Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ... New England Journal of Medicine 371 (21), 1963-1971, 2014 | 2168 | 2014 |
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012 | 1537 | 2012 |
| Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations J Gong, A Chehrazi-Raffle, S Reddi, R Salgia Journal for immunotherapy of cancer 6, 1-18, 2018 | 1232 | 2018 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1136 | 2011 |
| c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention JG Christensen, J Burrows, R Salgia Cancer letters 225 (1), 1-26, 2005 | 931 | 2005 |
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Cancer discovery 5 (8), 850-859, 2015 | 742 | 2015 |
| The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups MT Jaklitsch, FL Jacobson, JHM Austin, JK Field, JR Jett, S Keshavjee, ... The Journal of thoracic and cardiovascular surgery 144 (1), 33-38, 2012 | 714 | 2012 |
| c-Met: structure, functions and potential for therapeutic inhibition PC Ma, G Maulik, J Christensen, R Salgia Cancer and Metastasis Reviews 22, 309-325, 2003 | 706 | 2003 |
| Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non–small cell lung cancer PC Ma, R Jagadeeswaran, S Jagadeesh, MS Tretiakova, V Nallasura, ... Cancer research 65 (4), 1479-1488, 2005 | 679 | 2005 |
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ... Journal of Clinical Oncology 29 (19), 2660-2666, 2011 | 624 | 2011 |
| Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition G Maulik, A Shrikhande, T Kijima, PC Ma, PT Morrison, R Salgia Cytokine & growth factor reviews 13 (1), 41-59, 2002 | 621 | 2002 |
| c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions PC Ma, T Kijima, G Maulik, EA Fox, M Sattler, JD Griffin, BE Johnson, ... Cancer research 63 (19), 6272-6281, 2003 | 590 | 2003 |
| Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer J Rehman, HJ Zhang, PT Toth, Y Zhang, G Marsboom, Z Hong, R Salgia, ... The FASEB Journal 26 (5), 2175, 2012 | 585 | 2012 |
| Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer DVT Catenacci, MR Junttila, T Karrison, N Bahary, MN Horiba, SR Nattam, ... Journal of Clinical Oncology 33 (36), 4284-4292, 2015 | 515 | 2015 |
| Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with … SHI Ou, EL Kwak, C Siwak-Tapp, J Dy, K Bergethon, JW Clark, ... Journal of thoracic oncology 6 (5), 942-946, 2011 | 496 | 2011 |
| Targeting FTO suppresses cancer stem cell maintenance and immune evasion R Su, L Dong, Y Li, M Gao, L Han, M Wunderlich, X Deng, H Li, Y Huang, ... Cancer cell 38 (1), 79-96. e11, 2020 | 490 | 2020 |
| MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib JK Lennerz, EL Kwak, A Ackerman, M Michael, SB Fox, K Bergethon, ... Journal of clinical oncology 29 (36), 4803-4810, 2011 | 484 | 2011 |
| Molecular abnormalities in lung cancer. R Salgia, AT Skarin Journal of Clinical Oncology 16 (3), 1207-1217, 1998 | 451 | 1998 |
